Continuous, high-dose progestogen treatment of endometrial cancer.
The morphological effect of a high-dose progestogen (Depo-Provera) on highly differentiated endometrial carcinoma was studied. Thirteen patients were treated by progestogen only, given at the beginning of the treatment in a weekly dose of 1,000 mg for 3 month. Then, progestogen 500 mg was administered for 12 months. Nine patients were operated after the treatment; in 7 of them, a total histological regression was observed. Histological tests of the intraoperatively gained preparations showed 'disappearance' of the original carcinomatous process; only a serious atrophy of the endometrium could be detected.
D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000188:drug therapy* / Q000601:surgery / Q000648:ultrastructure; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004717:Endometrium / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008855:Microscopy, Electron, Scanning; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000648:ultrastructure
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone